Fulton Bank N.A. Decreases Stock Position in Natera, Inc. (NASDAQ:NTRA)

Fulton Bank N.A. reduced its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 19.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,449 shares of the medical research company’s stock after selling 808 shares during the quarter. Fulton Bank N.A.’s holdings in Natera were worth $438,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. KBC Group NV acquired a new stake in shares of Natera during the fourth quarter valued at $141,000. Avidity Partners Management LP grew its holdings in shares of Natera by 23.5% during the fourth quarter. Avidity Partners Management LP now owns 1,110,000 shares of the medical research company’s stock worth $69,530,000 after buying an additional 211,000 shares in the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of Natera by 180.7% during the fourth quarter. Cubist Systematic Strategies LLC now owns 224,026 shares of the medical research company’s stock worth $14,033,000 after buying an additional 144,212 shares in the last quarter. First Light Asset Management LLC acquired a new position in shares of Natera in the fourth quarter valued at approximately $10,391,000. Finally, Harbert Fund Advisors Inc. purchased a new position in shares of Natera during the fourth quarter valued at approximately $532,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several analyst reports. Morgan Stanley raised their price objective on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. TD Cowen raised their price target on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. UBS Group dropped their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Canaccord Genuity Group raised their target price on shares of Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Finally, Robert W. Baird boosted their target price on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $120.07.

Natera Trading Up 2.9 %

NASDAQ:NTRA opened at $131.93 on Wednesday. The company has a market cap of $16.20 billion, a PE ratio of -42.29 and a beta of 1.53. The business’s 50 day moving average is $119.52 and its two-hundred day moving average is $108.62. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $133.54.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The firm had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm’s revenue was up 58.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.97) earnings per share. On average, analysts predict that Natera, Inc. will post -1.96 EPS for the current year.

Insider Activity at Natera

In other Natera news, CFO Michael Burkes Brophy sold 499 shares of Natera stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $107.40, for a total value of $53,592.60. Following the completion of the transaction, the chief financial officer now directly owns 77,418 shares in the company, valued at $8,314,693.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Jonathan Sheena sold 12,000 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00. Following the completion of the transaction, the insider now directly owns 287,441 shares in the company, valued at $34,783,235.41. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Michael Burkes Brophy sold 499 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $107.40, for a total value of $53,592.60. Following the sale, the chief financial officer now directly owns 77,418 shares in the company, valued at approximately $8,314,693.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 51,738 shares of company stock valued at $6,040,584 in the last quarter. Insiders own 7.60% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.